Alimetry is a health technology startup based in Auckland, New Zealand, specializing in diagnostic solutions for disorders of gastrointestinal function. Founded in 2019 by Professor Greg O’Grady and Dr. Armen Gharibans, the company has developed a wearable gut health monitoring device designed to streamline the diagnosis of gastric disorders. As of October 2024, Alimetry has raised $18 million in a Series A2 funding round, which will be used to further commercialize their technology, particularly within the U.S. market.
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | Auckland, New Zealand |
| Founders | Prof. Greg O’Grady, Dr. Armen Gharibans |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | Matū, UniServices Ltd |
| Industry | Medical Devices, Healthtech |
| Number of Employees | Approximately 100 |
Alimetry began its journey within the Auckland Bioengineering Institute, emerging from extensive interdisciplinary research focused on digestive health. Established in 2019 by esteemed University of Auckland professors Greg O'Grady and Armen Gharibans, Alimetry capitalized on novel insights into gastric disorders to develop its flagship wearable diagnostic device. The company quickly partnered with academic and industry leaders, securing preliminary funding from the University of Auckland's Inventors’ Fund and Matū, a New Zealand venture capital firm, which provided the necessary resources to propel the startup toward clinical trials and regulatory approval.
Alimetry operates primarily in the health technology sector, with a business model focused on providing innovative diagnostic solutions for gastrointestinal disorders. The company's primary innovation is the development of a highly sensitive wearable device that employs Body Surface Gastric Mapping—a form of electrophysiological gastric monitoring. This device does not only facilitate early diagnosis but also integrates real-time AI-driven analytics, offering unprecedented accuracy.
Significant Milestones include:
As of 2024, Alimetry is experiencing significant growth, bolstered by its cutting-edge technology and successful penetration into the U.S. medical market. Alimetry continues to expand its operations through strategic partnerships with hospitals and clinics to enhance its market share. With its technology now being adopted internationally, Alimetry is poised as a leader in the non-invasive diagnostics industry. The company’s wearable device is uniquely advantageous in offering non-intrusive, rapid, and precise diagnostics, which strengthens its competitive position against traditional invasive techniques.
Alimetry stands at the forefront of medical diagnostics innovation, notably through its smart, wearable tech solutions that redefine gastrointestinal health assessments. With successful expansion into international markets, particularly the United States, and significant financial support, Alimetry is well-positioned to continue its trajectory of growth and technological advancements. Future developments are likely to focus on deeper AI integration and enhancing the global reach of its diagnostic services, potentially setting new standards within the health technology industry.